Wellington Group’s Takeda Pharmaceutical TAK Stock Holding History

Wellington Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,308	Closed	-$67.2K	–	436
2025 Q4	$67.2K	Buy	+4,308	New	+$61.6K	0.02%	225

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wellington Group's TAK Position: Q1 2026 in Review

Wellington Group sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 4,308 shares — an estimated $67.2K sold.

Wellington Group first reported a position in TAK in Q4 2025 and held it in 1 quarter. The position peaked at $67.2K in Q4 2025. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Wellington Group reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Wellington Group sold 4,308 Takeda Pharmaceutical shares in Q1 2026, an estimated $67.2K.
Wellington Group first reported a position in Takeda Pharmaceutical in Q4 2025 and held it in 1 quarter.
Wellington Group's Takeda Pharmaceutical position peaked at $67.2K in Q4 2025.
361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Wellington Group's 13F filing for Q1 2026, filed 22 May 2026.